

Electronic Supplementary Information

Copper-catalyzed Three-Component Reaction of *N*-Heteroaryl Aldehydes, Nitriles, and Water


Hanyang Bao, Bingwei Zhou, Hongwei Jin,* and Yunkui Liu*

State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, P. R. China
Email: jhwei828@zjut.edu.cn; ykuiliu@zjut.edu.cn;

Contents


1. 3 mmol-Scale synthesis of 3aa	S2
2. Reaction of 1a in CH ₃ CN-H ₂ O ¹⁸	S2-S3
3. Intermolecular Competition Experiment on 1a and 1a-d	S3-S4
4.1 Characterization of unknown starting materials	S4-S8
4.2 Characterization of 3ba-3va	S8-S14
4.3 Characterization of 3ad-3ag	S14-S15
4.4 Characterization of 7ba-7na	S15–S19
5. References	S19
6. ¹ H and ¹³ C NMR spectra of unknown starting materials.	S20-S47
7. ¹ H and ¹³ C NMR spectra of 3aa-va , 3ab-ag , 7aa-na , 8a , 1a-d	S48–S134

1. 3 mmol-scale synthesis of **3aa**



Procedure: **1a** (702.0 mg, 3 mmol), Cu(OTf)₂ (217.0 mg, 0.6 mmol), (NH₄)₂S₂O₈ (685.0 mg, 3 mmol), and CH₃CN/H₂O = 500/1 (V/V, 30 mL) were added to a 100-mL reaction tube. Then the reaction mixture was stirred at 60 °C for 12 h. Upon completion, the resulting mixture was diluted with CH₂Cl₂ (50 mL) and filtered through Celite. After evaporation of the solvent under vacuum, the residue was purified by column chromatography on silica gel (100-200 mesh) using petroleum ether-EtOAc (6:1-3:1) as eluent to give pure product **3aa** (610.0 mg, 70%).

2. Reaction of **1a** in CH₃CN-H₂O¹⁸ (5 equiv of H₂O¹⁸)



MS-analytical Results:





Figure S1. The MS-spectrum of **2a/2a-O¹⁸**

3. Intermolecular Competition Experiment on **1a** and **1a-d**.






Figure S2. The ¹H NMR of the Recovered Mixture of 1a and 1a-d

4.1 Characterization of unknown starting materials

3-(4-ethylphenyl)quinoxaline-2-carbaldehyde (1f): **1f** was synthesized according to the reported procedure¹ as yellow solid (2.0 mmol scale, 0.29 g, total 55% yield through a two-step process). m.p. 77.9-79.4 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.34 (s, 1H), 8.31 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.1$ Hz, 1H), 8.20 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.0$ Hz, 1H), 7.94-7.90 (m, 1H), 7.87-7.84 (m, 1H), 7.66-7.64 (m, 2H), 7.40 (d, $J = 8.2$ Hz, 2H), 2.77 (q, $J = 7.6$ Hz, 2H), 1.31 (t, $J = 7.6$ Hz, 3H). ¹³C {¹H} NMR (125 MHz, CDCl₃): δ 191.4, 154.6, 146.4, 145.0, 142.9, 140.9, 133.8, 133.0, 130.8, 130.3, 129.9, 129.3, 128.3, 28.8, 15.4. IR (potassium bromide) (ν, cm⁻¹): 1706 (C=O). HRMS (ESI) for C₁₇H₁₅N₂O [M + H]⁺: calcd: 263.1179, found: 263.1175.

3-(4-(benzyloxy)phenyl)quinoxaline-2-carbaldehyde (1h): **1h** was synthesized according to the reported procedure¹ as yellow solid (2.0 mmol scale, 0.41 g, total 60% yield through a two-step process). m.p. 130.5-132.6 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.34 (s, 1H), 8.30 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.0$ Hz, 1H), 8.19 (dd, $J_1 = 8.4$ Hz,

$J_2 = 0.9$ Hz, 1H), 7.93-7.90 (m, 1H), 7.86-7.83 (m, 1H), 7.72-7.69 (m, 2H), 7.49-7.35 (m, 5H), 7.18-7.15 (m, 2H), 5.18 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 191.5, 160.4, 154.0, 145.0, 142.9, 140.8, 136.5, 133.0, 131.6, 130.6, 130.3, 129.3, 129.0, 128.7, 128.2, 127.5, 115.2, 70.14. IR (potassium bromide) (ν , cm^{-1}): 1708 (C=O). HRMS (ESI) for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 341.1285, found: 341.1289.

3-(3-bromophenyl)quinoxaline-2-carbaldehyde (1i): **1i** was synthesized according to the reported procedure¹ as white solid (2.0 mmol scale, 0.45 g, total 72% yield through a two-step process). m.p. 176.3-177.1 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 8.32 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.0$ Hz, 1H), 8.22 (dd, $J_1 = 8.4$ Hz, $J_2 = 0.9$ Hz, 1H), 7.99-7.89 (m, 1H), 7.93-7.89 (m, 2H), 7.70-7.68 (m, 1H), 7.60-7.58 (m, 1H), 7.42 (t, $J = 7.9$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 191.3, 152.6, 144.8, 142.7, 141.1, 138.7, 133.4, 132.8, 132.5, 131.3, 130.3, 129.9, 129.4, 128.5, 122.7. IR (potassium bromide) (ν , cm^{-1}): 1710 (C=O). HRMS (ESI) for $\text{C}_{15}\text{H}_{10}\text{BrN}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 312.9971, found: 312.9978.

3-(3-chlorophenyl)quinoxaline-2-carbaldehyde (1j): **1j** was synthesized according to the reported procedure¹ as yellow solid (2.0 mmol scale, 0.36 g, total 68% yield through a two-step process). m.p. 172.9-174.5 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 8.32 (dd, $J_1 = 8.3$ Hz, $J_2 = 1.1$ Hz, 1H), 8.22 (dd, $J_1 = 8.2$ Hz, $J_2 = 1.2$ Hz, 1H), 7.99-7.96 (m, 1H), 7.93-7.90 (m, 1H), 7.74 (t, $J = 1.7$ Hz, 1H), 7.55-7.47 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 191.3, 152.7, 144.8, 142.7, 141.1, 138.5, 134.7, 133.4, 131.3, 130.3, 129.9, 129.70, 129.66, 129.4, 128.0. IR (potassium bromide) (ν , cm^{-1}): 1705 (C=O). HRMS (ESI) for $\text{C}_{15}\text{H}_{10}\text{ClN}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 269.0476, found: 269.0471.

3-(2-fluorophenyl)quinoxaline-2-carbaldehyde (1l): **1l** was synthesized according to the reported procedure¹ as yellow solid (2 mmol scale, 0.40 g, total 79% yield through a two-step process). m.p. 124.3-126.1 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.29 (d, $J = 1.1$ Hz, 1H), 8.31 (dd, $J_1 = 8.3$ Hz, $J_2 = 1.1$ Hz, 1H), 8.23 (dd, $J_1 = 8.3$ Hz, $J_2 = 1.0$ Hz, 1H), 7.96-7.88 (m, 2H), 7.75-7.71 (m, 1H), 7.56-7.51 (m, 1H), 7.38 (td, $J_1 = 7.5$ Hz, $J_2 = 1.0$ Hz, 1H), 7.21-7.18 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 191.2, 160.0 (d, $J = 247.9$ Hz), 148.4, 145.6, 143.2, 141.0, 133.1, 131.8 (d,

$J = 8.4$ Hz), 131.2, 131.1 (d, $J = 2.8$ Hz), 130.2, 129.5, 125.5 (d, $J = 14.7$ Hz), 124.9 (d, $J = 3.4$ Hz), 115.5 (d, $J = 21.6$ Hz). IR (potassium bromide) (ν , cm^{-1}): 1708 (C=O). HRMS (ESI) for $\text{C}_{15}\text{H}_{10}\text{FN}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 253.0772, found: 253.0777.

3-(2-bromophenyl)quinoxaline-2-carbaldehyde (1n): **1n** was synthesized according to the reported procedure¹ as yellow solid (2 mmol scale, 0.38 g, total 61% yield through a two-step process). m.p. 81.2-82.4 °C. ^1H NMR (500 MHz, CDCl_3): 10.24 (s, 1H), 8.36-8.34 (m, 1H), 8.25-8.23 (m, 1H), 7.99-7.92 (m, 2H), 7.70 (d, $J = 7.9$ Hz, 1H), 7.55-7.54 (m, 2H), 7.44-7.40 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 190.9, 153.1, 145.3, 142.8, 141.3, 138.3, 133.2, 132.7, 131.3, 130.9, 130.6, 130.3, 129.5, 128.0, 122.3. IR (potassium bromide) (ν , cm^{-1}): 1713 (C=O). HRMS (ESI) for $\text{C}_{15}\text{H}_{10}\text{BrN}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 312.9971, found: 312.9978.

3-chloroquinoxaline-2-carbaldehyde (1q): **1q** was synthesized according to the reported procedure¹ as white solid (2.0 mmol scale, 0.17 g, total 45% yield through a two-step process). m.p. 141.6-143.0 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.45 (s, 1H), 8.30 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.0$ Hz, 1H), 8.12 (dd, $J_1 = 8.4$ Hz, $J_2 = 0.9$ Hz, 1H), 8.01-7.97 (m, 1H), 7.94-7.90 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 189.0, 145.5, 143.1, 142.9, 140.7, 134.2, 131.4, 130.4, 128.4. IR (potassium bromide) (ν , cm^{-1}): 1706 (C=O). HRMS (ESI) for $\text{C}_9\text{H}_6\text{ClN}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 193.0163, found: 193.0167.

6,7-dibromo-3-phenylquinoxaline-2-carbaldehyde (1s): **1s** was synthesized according to the reported procedure¹ as yellow solid (2.0 mmol scale, 0.59 g, total 75% yield through a two-step process). m.p. 178.7-179.9 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.28 (s, 1H), 8.61 (s, 1H), 8.54 (s, 1H), 7.71-7.69 (m, 2H), 7.60-7.56 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 190.6, 155.3, 145.8, 141.8, 140.0, 135.9, 134.0, 133.4, 130.5, 130.4, 129.8, 128.8, 127.9. IR (potassium bromide) (ν , cm^{-1}): 1710 (C=O). HRMS (ESI) for $\text{C}_{15}\text{H}_9\text{Br}_2\text{N}_2\text{O}$ $[\text{M} + \text{H}]^+$: calcd: 390.9076, found: 390.9081.

3-(4-methoxyphenyl)-6,7-dimethylquinoxaline-2-carbaldehyde (1v): **1v** was synthesized according to the reported procedure¹ as yellow solid (2.0 mmol scale, 0.40 g, total 69% yield through a two-step process). m.p. 144.4-146.5 °C. ^1H NMR

(500 MHz, CDCl₃): δ 10.28 (s, 1H), 8.00 (s, 1H), 7.91 (s, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 2.53 (s, 6H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 191.6, 160.9, 153.5, 144.4, 144.0, 141.9, 141.5, 139.9, 131.4, 129.1, 129.0, 128.1, 114.1, 55.4, 20.7, 20.4. IR (potassium bromide) (ν , cm⁻¹): 1711 (C=O). HRMS (ESI) for C₁₈H₁₇N₂O₂ [M + H]⁺: calcd: 293.1285, found: 293.1279.

8-methyl-7-(trifluoromethyl)quinoline-2-carbaldehyde (6g): **6g** was synthesized from the oxidation of 2,8-dimethyl-7-(trifluoromethyl)quinolone with SeO₂ as white solid (2.0 mmol scale, 0.35 g, 73% yield). m.p. 94.3-97.2 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.26 (d, J = 0.8 Hz, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 3.09 (d, J = 1.9 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 193.7, 152.4, 146.7, 139.6, 137.7, 131.1, 130.0 (q, J = 29.9 Hz), 125.8, 125.0 (q, J = 5.4 Hz), 124.3 (q, J = 273.75 Hz), 118.6, 13.4 (d, J = 2.0 Hz). IR (potassium bromide) (ν , cm⁻¹): 1708 (C=O). HRMS (ESI) for C₁₂H₉F₃NO [M + H]⁺: calcd: 240.0631, found: 240.0637.

5,7-dimethylquinoline-2-carbaldehyde (6i): **6i** was synthesized from the oxidation of 2,5,7-trimethylquinoline with SeO₂ as white solid (2.0 mmol scale, 0.30 g, 81% yield). m.p. 88.6-89.9 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.20 (s, 1H), 8.37 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.85 (s, 1H), 7.33 (s, 1H), 2.67 (s, 3H), 2.55 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 194.0, 152.1, 148.6, 140.5, 134.4, 133.5, 132.0, 127.6, 127.4, 116.2, 21.8, 18.6. IR (potassium bromide) (ν , cm⁻¹): 1701 (C=O). HRMS (ESI) for C₁₂H₁₂NO [M + H]⁺: calcd: 186.0913, found: 186.0917.

3-chlorophenanthridine-6-carbaldehyde (6k): **6k** was synthesized from the oxidation of 3-chloro-6-methylphenanthridine with SeO₂ as white solid (2.0 mmol scale, 0.31 g, 64% yield). m.p. 134.8-135.8 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.27 (s, 1H), 9.28 (d, J = 8.3 Hz, 1H), 8.44 (d, J = 8.3 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.66-7.64 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 195.4, 151.2, 144.0, 135.0, 133.2, 131.6, 130.4, 130.3, 129.1, 127.2, 124.1, 123.7, 123.5, 121.9. IR (potassium bromide) (ν , cm⁻¹): 1708 (C=O). HRMS (ESI) for C₁₄H₉ClNO [M + H]⁺: calcd: 242.0367, found: 242.0361.

2-methylphenanthridine-6-carbaldehyde (6l): **6l** was synthesized from the oxidation of 2,6-dimethylphenanthridine with SeO₂ as white solid (2.0 mmol scale, 0.37 g, 84% yield). m.p. 134.8-135.8 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.35 (s, 1H), 9.36 (d, *J* = 8.4 Hz, 1H), 8.55 (d, *J* = 8.3 Hz, 1H), 8.28 (s, 1H), 8.15 (d, *J* = 8.3 Hz, 1H), 7.85-7.82 (m, 1H), 7.75-7.72 (m, 1H), 7.61 (dd, *J*₁ = 8.3 Hz, *J*₂ = 1.6 Hz, 1H), 2.65 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 195.7, 149.3, 141.6, 140.4, 132.9, 130.92, 130.91, 130.8, 128.5, 126.7, 125.3, 123.6, 121.78, 121.76, 22.29. IR (potassium bromide) (ν, cm⁻¹): 1690 (C=O). HRMS (ESI) for C₁₅H₁₂NO [M + H]⁺: calcd: 222.0913, found: 222.0918.

8-methylphenanthridine-6-carbaldehyde (6m): **6m** was synthesized from the oxidation of 6,8-dimethylphenanthridine with SeO₂ as white solid (2.0 mmol scale, 0.3 g, 69% yield). m.p. 111.3-112.2 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.43 (s, 1H), 9.23 (s, 1H), 8.61-8.57 (m, 2H), 8.34-8.32 (m, 1H), 7.83-7.81 (m, 2H), 7.75 (dd, *J*₁ = 8.5 Hz, *J*₂ = 1.5 Hz, 1H), 2.65 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 195.9, 150.0, 143.1, 139.1, 133.0, 131.5, 131.2, 129.8, 128.8, 126.2, 125.8, 123.8, 122.1, 121.8, 22.0. IR (potassium bromide) (ν, cm⁻¹): 1701 (C=O). HRMS (ESI) for C₁₅H₁₂NO [M + H]⁺: calcd: 222.0913, found: 222.0915.

4.2 Characterization of 3ba-3va

N-acetyl-3-(4-bromophenyl)quinoxaline-2-carboxamide (3ba): Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (105.5 mg, 95%). m.p. 212.9–213.8 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.22 (s, 1H), 8.23–8.19 (m, 2H), 7.99–7.90 (m, 2H), 7.68–7.66 (m, 2H), 7.56–7.54 (m, 2H), 2.57 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.2, 162.6, 153.4, 143.1, 141.3, 139.0, 137.3, 133.2, 131.48, 131.46, 130.6, 129.42, 129.41, 124.1, 25.4; IR (potassium bromide) (ν, cm⁻¹): 3345 (N-H), 1748 (C=O). HRMS (ESI) for C₁₇H₁₃BrN₃O₂ [M + H]⁺: calcd: 370.0186, found: 370.0180.

N-acetyl-3-(4-chlorophenyl)quinoxaline-2-carboxamide (3ca): Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (94.2 mg, 97%). m.p. 187.2–188.6 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.31 (s, 1H), 8.22–8.19

(m, 2H), 7.98–7.95 (m, 1H), 7.93–7.89 (m, 1H), 7.61 (d, $J = 8.5$ Hz, 2H), 7.51 (d, $J = 8.0$ Hz, 2H), 2.57 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.1, 162.7, 153.3, 143.1, 141.4, 139.0, 136.8, 135.7, 133.2, 131.4, 130.4, 129.40, 129.38, 128.5, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3349 (N-H), 1748 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{13}\text{ClN}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 326.0691, found: 326.0684.

***N*-acetyl-3-(4-fluorophenyl)quinoxaline-2-carboxamide (3da):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (90.9 mg, 98%). m.p. 180.7–182.8 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 8.20 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.17 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.0$ Hz, 1H), 7.96–7.87 (m, 2H), 7.68–7.65 (m, 2H), 7.24–7.19 (m, 2H), 2.55 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.1, 163.5 (d, $J_{\text{C-F}} = 247.5$ Hz), 153.3, 143.0, 141.6, 138.9, 134.3 (d, $J_{\text{C-F}} = 3.75$ Hz), 133.0, 131.2, 131.0, 130.9, 129.315, 129.307, 115.4 (d, $J_{\text{C-F}} = 21.25$ Hz), 25.3; IR (potassium bromide) (ν , cm^{-1}): 3357 (N-H), 1748 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{13}\text{FN}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 310.0986, found: 310.0994.

***N*-acetyl-3-(*p*-tolyl)quinoxaline-2-carboxamide (3ea):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (61.4 mg, 67%). m.p. 162.3–164.0 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.25 (s, 1H), 8.21 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.5$ Hz, 1H), 8.17 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.0$ Hz, 1H), 7.95–7.85 (m, 2H), 7.58 (d, $J = 8.0$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 2.57 (s, 3H), 2.47 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 163.0, 154.3, 143.1, 142.0, 139.5, 138.8, 135.4, 132.8, 130.9, 129.4, 129.3, 129.1, 128.8, 25.4, 21.5. IR (potassium bromide) (ν , cm^{-1}): 3335 (N-H), 1750 (C=O). HRMS (ESI) for $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 306.1237, found: 306.1245.

***N*-acetyl-3-(4-ethylphenyl)quinoxaline-2-carboxamide (3fa):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (60.0 mg, 63%). m.p. 165.4–166.1 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.28 (s, 1H), 8.20 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.16 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 7.93–7.90 (m, 1H), 7.87–7.84 (m, 1H), 7.61 (d, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 2H), 2.77 (q, $J = 7.5$ Hz, 2H), 2.56 (s, 3H), 1.31 (t, $J = 7.5$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.2, 163.1, 154.2, 145.7, 143.0, 142.0, 138.7, 135.5, 132.7, 130.9, 129.3, 129.2,

128.9, 127.9, 28.7, 25.4, 15.2. IR (potassium bromide) (ν , cm^{-1}): 3239 (N-H), 1738 (C=O). HRMS (ESI) for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 320.1394, found: 320.1387.

***N*-acetyl-3-(4-methoxyphenyl)quinoxaline-2-carboxamide (3ga):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (64.0 mg, 66%). m.p. 136.7–138.3 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.23 (s, 1H), 8.19 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.15 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.5$ Hz, 1H), 7.94–7.90 (m, 1H), 7.87–7.84 (m, 1H), 7.66 (d, $J = 8.5$ Hz, 2H), 7.05 (d, $J = 8.5$ Hz, 2H), 3.90 (s, 3H), 2.58 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 163.2, 160.8, 153.8, 143.1, 141.9, 138.6, 132.8, 130.8, 130.6, 130.4, 129.29, 129.27, 113.9, 55.4, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3330 (N-H), 1712 (C=O). HRMS (ESI) for $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd: 322.1186, found: 322.1181.

***N*-acetyl-3-(4-(benzyloxy)phenyl)quinoxaline-2-carboxamide (3ha):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (103.0 mg, 86%). m.p. 149.2–150.2 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.25 (s, 1H), 8.20–8.14 (m, 2H), 7.94–7.84 (m, 2H), 7.68–7.65 (m, 2H), 7.49–7.35 (m, 5H), 7.15–7.12 (m, 2H), 5.16 (s, 2H), 2.58 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 163.2, 160.0, 153.7, 143.1, 141.9, 138.6, 136.7, 132.8, 130.8, 130.63, 130.58, 129.3, 129.2, 128.6, 128.1, 127.5, 114.7, 70.0, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3325 (N-H), 1708 (C=O). HRMS (ESI) for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd: 398.1499, found: 398.1504.

***N*-acetyl-3-(3-bromophenyl)quinoxaline-2-carboxamide (3ia):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (98.2 mg, 88%). m.p. 179.8–181.6 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 8.22 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.20 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.0$ Hz, 1H), 7.99–7.95 (m, 1H), 7.94–7.90 (m, 1H), 7.83 (t, $J = 2.0$ Hz, 1H), 7.86–7.64 (m, 1H), 7.57–7.54 (m, 1H), 7.39 (t, $J = 8.0$ Hz, 1H), 2.57 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.2, 162.6, 152.9, 143.0, 141.5, 140.3, 139.1, 133.2, 132.3, 131.8, 131.6, 129.6, 129.5, 129.4, 127.7, 122.4, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3301 (N-H), 1744 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{13}\text{BrN}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 370.0186, found: 370.0180.

***N*-acetyl-3-(3-chlorophenyl)quinoxaline-2-carboxamide (3ja):** Purified by

column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (93.0 mg, 95%). m.p. 169.4–171.1 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.33 (s, 1H), 8.23–8.18 (m, 2H), 7.98–7.90 (m, 2H), 7.67 (t, *J* = 1.5 Hz, 1H), 7.52–7.43 (m, 3H), 2.56 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.1, 162.6, 152.9, 142.9, 141.5, 140.0, 139.0, 134.2, 133.1, 131.5, 129.38, 129.35, 128.9, 127.1, 25.3. IR (potassium bromide) (ν, cm⁻¹): 3312 (N-H), 1745 (C=O). HRMS (ESI) for C₁₇H₁₃ClN₃O₂ [M + H]⁺: calcd: 326.0691, found: 326.0683.

***N*-acetyl-3-(3-methoxyphenyl)quinoxaline-2-carboxamide (3ka):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (75.0 mg, 78%); m.p. 142.4–143.1 °C; ¹H NMR (500 MHz, CDCl₃): δ 10.22 (s, 1H), 8.23 (dd, *J*₁ = 8.5 Hz, *J*₂ = 1.0 Hz, 1H), 8.19 (dd, *J*₁ = 8.5 Hz, *J*₂ = 1.0 Hz, 1H), 7.97–7.88 (m, 2H), 7.44 (t, *J* = 8.0 Hz, 1H), 7.23–7.19 (m, 2H), 7.09–7.06 (m, 1H), 3.90 (s, 3H), 2.56 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 172.2, 162.8, 159.5, 154.1, 143.0, 142.1, 139.6, 139.0, 132.9, 131.2, 129.4, 129.34, 129.33, 121.3, 115.1, 114.4, 55.4, 25.4; IR (potassium bromide) (ν, cm⁻¹): 3286 (N-H), 1712 (C=O). HRMS (ESI) for C₁₈H₁₆N₃O₃ [M + H]⁺: calcd: 322.1186, found: 322.1190.

***N*-acetyl-3-(2-fluorophenyl)quinoxaline-2-carboxamide (3la):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (80.0 mg, 86%). m.p. 123.3–125.6 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.29 (s, 1H), 8.24–8.18 (m, 2H), 7.97–7.89 (m, 2H), 7.78–7.75 (m, 1H), 7.55–7.50 (m, 1H), 7.40–7.37 (m, 1H), 7.17 (t, *J* = 4.0 Hz, 1H), 2.58 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.2, 162.4, 160.0 (d, *J* = 245.0 Hz), 149.0, 143.4, 142.4, 138.9, 132.9, 131.43, 131.35, 130.4 (d, *J* = 2.5 Hz), 129.41, 129.39, 126.8 (d, *J* = 15.0 Hz), 124.7 (d, *J* = 2.5 Hz), 115.2 (d, *J* = 22.5 Hz), 25.3. IR (potassium bromide) (ν, cm⁻¹): 3248 (N-H), 1733 (C=O). HRMS (ESI) for C₁₇H₁₃FN₃O₂ [M + H]⁺: calcd: 310.0986, found: 310.0980.

***N*-acetyl-3-(2-methoxyphenyl)quinoxaline-2-carboxamide (3ma):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (81.9 mg, 85%). m.p. 143.8–144.9 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.05 (s, 1H), 8.22 (dd, *J*₁ = 8.5 Hz, *J*₂ = 1.0 Hz, 1H), 8.17 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.0 Hz, 1H), 7.92–7.85 (m, 2H), 7.74 (dd, *J*₁ = 7.5 Hz, *J*₂ = 1.5 Hz, 1H), 7.53–7.49 (m, 1H), 7.24–7.21 (m, 1H), 6.98 (d,

$J = 8.5$ Hz, 1H), 3.76 (s, 3H), 2.57 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.4, 163.1, 156.4, 151.3, 144.2, 143.5, 138.7, 132.2, 131.2, 130.7, 130.0, 129.34, 129.31, 127.8, 121.6, 110.5, 55.0, 25.3. IR (potassium bromide) (ν , cm^{-1}): 3309 (N-H), 1709 (C=O). HRMS (ESI) for $\text{C}_{18}\text{H}_{16}\text{N}_3\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd: 322.1186, found: 322.1180.

***N*-acetyl-3-(2-bromophenyl)quinoxaline-2-carboxamide (3na):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (98.8 mg, 89%). m.p. 165.9–167.0 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.41 (s, 1H), 8.26–8.22 (m, 2H), 7.99–7.93 (m, 2H), 7.61 (d, $J = 7.5$ Hz, 1H), 7.57–7.53 (m, 2H), 7.42–7.38 (m, 1H) 2.56 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.2, 162.0, 153.5, 143.1, 141.8, 139.8, 139.1, 133.0, 132.3, 131.6, 130.4, 129.8, 129.5, 129.4, 127.8, 122.1, 25.3. IR (potassium bromide) (ν , cm^{-1}): 3275 (N-H), 1740 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{13}\text{BrN}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 370.0186, found: 370.0192.

***N*-acetylquinoxaline-2-carboxamide (3oa):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (55.0 mg, 85%). m.p. 101.3–103.3 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.31 (s, 1H), 9.66 (s, 1H), 8.20 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.14 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 7.94–7.87 (m, 2H), 2.69 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.8, 162.0, 144.4, 143.5, 141.5, 139.9, 132.7, 131.4, 129.8, 129.5, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3247 (N-H), 1711 (C=O). HRMS (ESI) for $\text{C}_{11}\text{H}_{10}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 216.0768, found: 216.0775.

***N*-acetyl-3-methylquinoxaline-2-carboxamide (3pa):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (30.7 mg, 45%). m.p. 144.8–147.9 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.80 (s, 1H), 8.11–8.08 (m, 2H), 7.92–7.80 (m, 2H), 3.14 (s, 3H), 2.66 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.1, 163.0, 154.6, 143.5, 140.7, 138.8, 132.8, 130.4, 129.4, 128.5, 25.4, 24.9. IR (potassium bromide) (ν , cm^{-1}): 3255 (N-H), 1711 (C=O). HRMS (ESI) for $\text{C}_{12}\text{H}_{12}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 230.0924, found: 230.0931.

***N*-acetyl-3-chloroquinoxaline-2-carboxamide (3qa):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a red solid (47.0 mg, 63%). m.p. 162.5–163.6 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.21 (s, 1H), 8.16 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.11 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 7.99–7.89 (m, 2H), 2.66 (s,

3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.0, 162.8, 145.2, 143.1, 140.1, 138.5, 134.0, 131.7, 129.4, 128.4, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3301 (N-H), 1742 (C=O). HRMS (ESI) for $\text{C}_{11}\text{H}_9\text{ClN}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 250.0378, found: 250.0385.

***N*-acetyl-6,7-dichloro-3-phenylquinoxaline-2-carboxamide (3ra):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (98.5 mg, 91%). m.p. 174.0–175.3 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.01 (s, 1H), 8.34 (s, 1H), 8.30 (s, 1H), 7.67–7.65 (m, 2H), 7.56–7.52 (m, 3H), 2.52 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.9, 162.8, 156.1, 143.5, 141.6, 137.8, 137.5, 137.4, 136.0, 129.94, 129.87, 129.7, 128.9, 128.4, 25.3. IR (potassium bromide) (ν , cm^{-1}): 3250 (N-H), 1712 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 360.0301, found: 360.0309.

***N*-acetyl-6,7-dibromo-3-phenylquinoxaline-2-carboxamide (3sa):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (84.8 mg, 73%). m.p. 198.9–201.3 °C. ^1H NMR (500 MHz, CDCl_3): δ 9.99 (s, 1H), 8.53 (s, 1H), 8.49 (s, 1H), 7.67–7.65 (m, 2H), 7.56–7.51 (m, 3H), 2.52 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.8, 162.8, 156.1, 143.6, 141.9, 138.0, 137.4, 133.4, 133.1, 130.1, 129.9, 128.9, 128.4, 128.1, 25.3. IR (potassium bromide) (ν , cm^{-1}): 3256 (N-H), 1711 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{12}\text{Br}_2\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 447.9291, found: 447.9283.

***N*-acetyl-6,7-dimethyl-3-phenylquinoxaline-2-carboxamide (3ta):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (60.3 mg, 63%). m.p. 138.0–139.4 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.37 (s, 1H), 7.96 (s, 1H), 7.90 (s, 1H), 7.64–7.62 (m, 2H), 7.52–7.51 (m, 3H), 2.56–2.55 (m, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 163.0, 153.6, 144.3, 142.13, 142.08, 140.6, 138.6, 137.9, 129.1, 128.8, 128.3, 128.14, 128.05, 25.4, 20.7, 20.4. IR (potassium bromide) (ν , cm^{-1}): 3307 (N-H), 1708 (C=O). HRMS (ESI) for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 320.1394, found: 320.1399.

***N*-acetyl-6,7-dimethyl-3-(*p*-tolyl)quinoxaline-2-carboxamide (3ua):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (58.4 mg, 58%). m.p. 177.2–177.9 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 2.56 (s, 3H),

2.550 (s, 3H), 2.548 (s, 3H), 2.45 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.4, 163.2, 153.6, 144.2, 142.1, 141.9, 140.7, 139.1, 137.8, 135.7, 128.9, 128.8, 128.2, 128.0, 25.4, 21.4, 20.7, 20.4. IR (potassium bromide) (ν , cm^{-1}): 3329 (N-H), 1738 (C=O). HRMS (ESI) for $\text{C}_{20}\text{H}_{20}\text{N}_3\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 334.1550, found: 334.1557.

***N*-acetyl-3-(4-methoxyphenyl)-6,7-dimethylquinoxaline-2-carboxamide (3va):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (61.2 mg, 58%). m.p. 150.0–151.3 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.32 (s, 1H), 7.93 (s, 1H), 7.88 (s, 1H), 7.63–7.61 (m, 2H), 7.05–7.02 (m, 2H), 3.90 (s, 3H), 2.57 (s, 3H), 2.56 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.4, 163.4, 160.5, 153.1, 144.2, 142.2, 141.8, 140.7, 137.7, 130.9, 130.5, 128.2, 128.1, 113.8, 55.3, 25.4, 20.7, 20.4. IR (potassium bromide) (ν , cm^{-1}): 3378 (N-H), 1655 (C=O). HRMS (ESI) for $\text{C}_{20}\text{H}_{20}\text{N}_3\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd: 350.1499, found: 350.1491.

4.3 Characterization of 3ad-3ag

***N*-(3-methoxypropanoyl)-3-phenylquinoxaline-2-carboxamide (3ad):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (29.8 mg, 30%). m.p. 128.5–130.0 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.38 (s, 1H), 8.22 (d, J = 8.0 Hz, 1H), 8.19–8.17 (m, 1H), 7.95–7.86 (m, 2H), 7.69–7.67 (m, 2H), 7.53–7.52 (m, 3H), 3.72 (t, J = 6.0 Hz, 2H), 3.42 (s, 3H), 3.046 (t, J = 5.5 Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.2, 163.3, 154.0, 142.9, 139.0, 138.1, 132.6, 131.0, 129.4, 129.35, 129.30, 128.9, 128.3, 67.2, 58.9, 37.9. IR (potassium bromide) (ν , cm^{-1}): 3276 (N-H), 1693 (C=O). HRMS (ESI) for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd: 336.1343, found: 336.1350.

***N*-acryloyl-3-phenylquinoxaline-2-carboxamide (3ae):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (25.1 mg, 27%). m.p. 193.0–194.2 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.27 (s, 1H), 8.25–8.21 (m, 2H), 7.97–7.89 (m, 2H), 7.69–7.67 (m, 2H), 7.54–7.53 (m, 3H), 7.25–7.22 (m, 1H), 6.61 (dd, J_1 = 17.0 Hz, J_2 = 1.5 Hz, 1H), 5.93 (dd, J_1 = 10.0 Hz, J_2 = 1.5 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 166.1, 154.4, 143.1, 138.9, 138.3, 132.9, 132.1, 131.1, 129.6, 129.5, 129.4, 128.9, 128.3, 113.6. IR (potassium bromide) (ν , cm^{-1}):

3235 (N-H), 1727 (C=O). HRMS (ESI) for $C_{18}H_{14}N_3O_2$ $[M + H]^+$: calcd: 304.1081, found: 304.1089.

***N*-benzoyl-3-phenylquinoxaline-2-carboxamide (3af):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (88.0 mg, 83%). m.p. 145.7–148.6 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.53 (s, 1H), 8.23 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.0$ Hz, 1H), 8.18–8.16 (m, 1H), 7.91–7.82 (m, 4H), 7.78–7.76 (m, 2H), 7.61–7.58 (m, 1H), 7.49–7.45 (m, 5H). $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 165.3, 165.8, 153.1, 145.2, 142.6, 139.2, 137.6, 133.4, 132.3, 132.0, 130.6, 129.43, 129.40, 129.2, 129.0, 128.9, 128.4, 127.9. IR (potassium bromide) (ν , cm^{-1}): 3251 (N-H), 1681 (C=O). HRMS (ESI) for $C_{22}H_{16}N_3O_2$ $[M + H]^+$: calcd: 354.1237, found: 354.1242.

***N*-(4-methoxybenzoyl)-3-phenylquinoxaline-2-carboxamide (3ag):** Purified by column chromatography (petroleum ether/EtOAc, 6/1-3/1) as a white solid (67.8 mg, 59%). m.p. 140.3–142.1 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.38 (s, 1H), 8.22 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.0$ Hz, 1H), 8.16 (dd, $J_1 = 8.3$ Hz, $J_2 = 1.1$ Hz, 1H), 7.89–7.77 (m, 6H), 7.47–7.43 (m, 3H), 6.92 (d, $J = 8.9$ Hz, 2H), 3.86 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 166.8, 164.7, 163.9, 152.9, 146.0, 142.5, 139.4, 137.7, 131.8, 130.6, 130.3, 129.5, 129.5, 129.3, 129.1, 128.5, 124.3, 114.2, 55.60. IR (potassium bromide) (ν , cm^{-1}): 3277 (N-H), 1694 (C=O). HRMS (ESI) for $C_{23}H_{18}N_3O_3$ $[M + H]^+$: calcd: 384.1343, found: 384.1351.

4.4 Characterization of 7ba-7na

***N*-acetyl-6-methylquinoline-2-carboxamide (7ba):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (58.9 mg, 72%). m.p. 135.3–136.7 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.70 (s, 1H), 8.24 (s, 2H), 8.00 (d, $J = 8.5$ Hz, 1H), 7.64–7.62 (m, 2H), 2.66 (s, 3H), 2.57 (s, 3H). $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 172.1, 163.1, 146.7, 144.8, 139.4, 137.2, 133.1, 129.9, 129.5, 126.5, 118.7, 25.3, 21.8. IR (potassium bromide) (ν , cm^{-1}): 3323 (N-H), 1706 (C=O). HRMS (ESI) for $C_{13}H_{13}N_2O_2$ $[M + H]^+$: calcd: 229.0972, found: 229.0964.

***N*-acetyl-6-methoxyquinoline-2-carboxamide (7ca):** Purified by column

chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (52.0 mg, 71%). m.p. 138.4–139.6 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.60 (s, 1H), 8.19–8.15 (m, 2H), 7.94 (d, *J* = 9.0 Hz, 1H), 7.40 (dd, *J*₁ = 9.5 Hz, *J*₂ = 2.5 Hz, 1H), 7.07 (d, *J* = 2.5 Hz, 1H), 3.94 (s, 3H), 2.64 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.1, 163.1, 159.6, 145.1, 142.2, 136.3, 131.23, 131.20, 123.9, 119.1, 104.7, 55.6, 25.3. IR (potassium bromide) (ν, cm⁻¹): 3329 (N-H), 1709 (C=O). HRMS (ESI) for C₁₃H₁₃N₂O₃ [M + H]⁺: calcd: 245.0921, found: 245.0930.

***N*-acetyl-6-fluoroquinoline-2-carboxamide (7da):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (64.0 mg, 92%). m.p. 143.3–145.3 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.61 (s, 1H), 8.31 (s, 2H), 8.16–8.13 (m, 1H), 7.61–7.57 (m, 1H), 7.52 (dd, *J*₁ = 8.5 Hz, *J*₂ = 3.0 Hz, 1H), 2.87 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.1, 162.8, 161.8 (d, *J*_{C-F} = 252.5 Hz), 147.2 (d, *J*_{C-F} = 3.75 Hz), 143.3, 137.4 (d, *J*_{C-F} = 5.0 Hz), 132.6 (d, *J*_{C-F} = 10.0 Hz), 130.7 (d, *J*_{C-F} = 10.0 Hz), 121.3 (d, *J*_{C-F} = 26.25 Hz), 119.5, 110.9 (d, *J*_{C-F} = 21.25 Hz), 25.3. IR (potassium bromide) (ν, cm⁻¹): 3318 (N-H), 1713 (C=O). HRMS (ESI) for C₁₂H₁₀FN₂O₂ [M + H]⁺: calcd: 233.0721, found: 233.0730.

***N*-acetyl-6-bromoquinoline-2-carboxamide (7ea):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (61.4 mg, 70%). m.p. 141.3–143.4 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.59 (s, 1H), 8.30 (d, *J* = 8.5 Hz, 1H), 8.26 (d, *J* = 8.5 Hz, 1H), 8.05 (d, *J* = 2.0 Hz, 1H), 7.97 (d, *J* = 9.0 Hz, 1H), 7.85 (dd, *J*₁ = 9.0 Hz, *J*₂ = 2.0 Hz, 1H), 2.66 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.1, 162.7, 148.0, 144.7, 137.1, 134.3, 131.4, 130.7, 129.8, 123.4, 119.6, 25.4. IR (potassium bromide) (ν, cm⁻¹): 3311 (N-H), 1711 (C=O). HRMS (ESI) for C₁₂H₁₀BrN₂O₂ [M + H]⁺: calcd: 292.9920, found: 292.9929.

***N*-acetyl-6-iodoquinoline-2-carboxamide (7fa):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (72.0 mg, 71%). m.p. 179.0–180.6 °C. ¹H NMR (500 MHz, CDCl₃): δ 10.62 (s, 1H), 8.24–8.32 (m, 2H), 8.27 (d, *J* = 8.5 Hz, 1H), 8.06 (dd, *J*₁ = 9.0 Hz, *J*₂ = 2.0 Hz, 1H), 7.87 (d, *J* = 9.0 Hz, 1H), 2.68 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.1, 162.8, 148.2, 145.2, 139.6, 136.9, 136.6, 131.3, 131.2, 119.6, 95.4, 25.4. IR (potassium bromide) (ν, cm⁻¹):

3325 (N-H), 1691 (C=O). HRMS (ESI) for $C_{12}H_{10}IN_2O_2$ $[M + H]^+$: calcd: 340.9781, found: 340.9786.

***N*-acetyl-7-methyl-8-(trifluoromethyl)quinoline-2-carboxamide (7ga):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (28.2 mg, 35%). m.p. 148.2–149.6 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.47 (s, 1H), 8.41 (s, 2H), 7.88–7.83 (m, 2H), 3.00 (d, $J = 2.0$ Hz, 3H), 2.69 (s, 3H). $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 171.9, 162.7, 147.8, 145.0, 138.7, 138.5 (d, $J_{C-F} = 1.25$ Hz), 130.9, 130.4 (q, $J_{C-F} = 28.75$ Hz), 125.9, 124.9 (q, $J_{C-F} = 5.0$ Hz), 124.1 (q, $J_{C-F} = 273.75$ Hz), 120.3, 25.4, 13.6 (d, $J_{C-F} = 1.25$ Hz). IR (potassium bromide) (ν , cm^{-1}): 3344 (N-H), 1716 (C=O). HRMS (ESI) for $C_{14}H_{12}F_3N_2O_2$ $[M + H]^+$: calcd: 297.0845, found: 297.0850.

***N*-acetyl-8-bromoquinoline-2-carboxamide (7ha):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (27.7 mg, 31%). m.p. 145.9–147.4 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.72 (s, 1H), 8.42 (d, $J = 8.5$ Hz, 1H), 8.38 (d, $J = 8.5$ Hz, 1H), 8.16 (dd, $J_1 = 7.5$ Hz, $J_2 = 1.5$ Hz, 1H), 7.91 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.0$ Hz, 1H), 7.58–7.55 (m, 1H), 2.68 (s, 3H). $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 171.8, 162.7, 148.3, 143.4, 138.9, 134.3, 131.1, 129.4, 127.5, 125.6, 119.7, 25.4. IR (potassium bromide) (ν , cm^{-1}): 3341 (N-H), 1707 (C=O). HRMS (ESI) for $C_{12}H_{10}BrN_2O_2$ $[M + H]^+$: calcd: 292.9920, found: 292.9928.

***N*-acetyl-5,7-dimethylquinoline-2-carboxamide (7ia):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (45.0 mg, 62%). m.p. 128.1–130.3 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.74 (s, 1H), 8.45 (d, $J = 8.5$ Hz, 1H), 8.23 (d, $J = 8.5$ Hz, 1H), 7.75 (s, 1H), 7.34 (s, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.55 (s, 3H). $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 172.1, 163.3, 147.0, 146.9, 140.9, 134.32, 134.28, 131.8, 127.4, 126.9, 117.6, 25.4, 21.8, 18.5. IR (potassium bromide) (ν , cm^{-1}): 3312 (N-H), 1703 (C=O). HRMS (ESI) for $C_{14}H_{15}N_2O_2$ $[M + H]^+$: calcd: 243.1128, found: 243.1136.

***N*-acetylphenanthridine-6-carboxamide (7ja):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (55.4 mg, 70%). m.p. 148.9–150.3 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.93 (s, 1H), 9.58 (d, $J = 8.5$

Hz, 1H), 8.69 (d, $J = 8.5$ Hz, 1H), 8.63–8.61 (m, 1H), 8.23–8.21 (m, 1H), 7.95–7.92 (m, 1H), 7.83–7.78 (m, 3H), 2.72 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 164.2, 146.1, 141.3, 134.0, 131.4, 130.8, 129.6, 129.3, 128.5, 128.2, 126.1, 124.2, 122.2, 122.1, 25.5. IR (potassium bromide) (v, cm^{-1}): 3258 (N-H), 1709 (C=O). HRMS (ESI) for $\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 265.0972, found: 265.0968.

***N*-acetyl-3-chlorophenanthridine-6-carboxamide (7ka):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (49.0 mg, 55%). m.p. 223.9–225.0 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.78 (s, 1H), 9.55 (d, $J = 8.5$ Hz, 1H), 8.62 (d, $J = 8.0$ Hz, 1H), 8.52 (d, $J = 9.0$ Hz, 1H), 8.19 (d, $J = 2.5$ Hz, 1H), 7.96–7.93 (m, 1H), 7.83–7.80 (m, 1H), 7.75 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.5$ Hz, 1H), 2.71 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.1, 163.8, 147.3, 141.8, 136.2, 133.7, 131.9, 130.2, 129.7, 128.8, 128.5, 124.5, 124.0, 123.6, 122.1, 25.5. IR (potassium bromide) (v, cm^{-1}): 3239 (N-H), 1705 (C=O). HRMS (ESI) for $\text{C}_{16}\text{H}_{12}\text{ClN}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 299.0582, found: 299.0576.

***N*-acetyl-2-methylphenanthridine-6-carboxamide (7la):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (50.4 mg, 61%). m.p. 131.9–133.7 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.93 (s, 1H), 9.57 (dd, $J_1 = 8.5$ Hz, $J_2 = 0.5$ Hz, 1H), 8.65 (d, $J = 8.5$ Hz, 1H), 8.37 (s, 1H), 8.07 (d, $J = 8.5$ Hz, 1H), 7.91–7.88 (m, 1H), 7.79–7.75 (m, 1H), 7.63 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.0$ Hz, 1H), 2.71 (s, 3H), 2.68 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 164.3, 145.0, 140.2, 139.6, 133.7, 131.2, 131.0, 130.5, 128.3, 128.1, 126.0, 124.4, 122.1, 121.7, 25.5, 22.3. IR (potassium bromide) (v, cm^{-1}): 3305 (N-H), 1708 (C=O). HRMS (ESI) for $\text{C}_{17}\text{H}_{15}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd: 279.1128, found: 279.1135.

***N*-acetyl-8-methylphenanthridine-6-carboxamide (7ma):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (52.3 mg, 63%). m.p. 135.7–137.6 °C. ^1H NMR (500 MHz, CDCl_3): δ 10.95 (s, 1H), 9.37 (s, 1H), 8.59–8.58 (m, 2H), 8.21–8.18 (m, 1H), 7.81–7.78 (m, 2H), 7.76 (dd, $J_1 = 8.5$ Hz, $J_2 = 1.5$ Hz, 1H), 2.72 (s, 3H), 2.65 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 164.3, 145.7, 140.9, 138.8, 133.2, 132.0, 130.7, 129.6, 128.9, 127.5, 126.2, 124.4, 122.0, 25.5, 22.0. IR (potassium bromide) (v, cm^{-1}): 3308 (N-H), 1714 (C=O). HRMS


(ESI) for $C_{17}H_{15}N_2O_2$ $[M + H]^+$: calcd: 279.1128, found: 279.1133.


***N*-acetylpicolinamide (7na):** Purified by column chromatography (petroleum ether/EtOAc, 10/1-6/1) as a white solid (27.0 mg, 55%). m.p. 74.1-76.3 °C. 1H NMR (500 MHz, $CDCl_3$): δ 10.47 (s, 1H), 8.62 (ddd, $J_1 = 4.8$ Hz, $J_2 = 1.6$ Hz, $J_3 = 0.9$ Hz, 1H), 8.26 (dt, $J_1 = 7.8$ Hz, $J_2 = 1.0$ Hz, 1H), 7.93 (td, $J_1 = 7.7$ Hz, $J_2 = 1.7$ Hz, 1H), 7.55 (ddd, $J_1 = 7.6$ Hz, $J_2 = 4.8$ Hz, $J_3 = 1.2$ Hz, 1H), 2.52 (s, 3H). ^{13}C NMR (125 MHz, $CDCl_3$): δ 172.0, 162.9, 148.4, 148.2, 137.8, 127.6, 123.1, 25.3. IR (potassium bromide) (ν , cm^{-1}): 3348 (N-H), 1711 (C=O). HRMS (ESI) for $C_8H_9N_2O_2$ $[M + H]^+$: calcd: 165.0659, found: 165.0654.


5. References


[1] Y. Liu, B. Jiang, W. Zhang and Z. Xu, *J. Org. Chem.*, 2013, **78**, 966.


6. ^1H and ^{13}C NMR spectra of unknown starting materials.





















































































7. ^1H and ^{13}C NMR spectra of 3aa-va, 3ab-ag, 7aa-na, 8a, 1a-d









































161019
BHY-2-4OCH3 CDCl3 1019










































161130
BHY-2-2Br CDCl₃ 1130





3na



























161115
BHY-2-diBr CDCl3 1115





3sa










































































































喹啉


BHY-k-8Br CDCl₃ 0113



















161230
BHY-F-3Cl CDCl₃ 0103









161130
BHY-2-F-R24CH3 CDCl3 1130

